# Global Cerebral Adrenoleukodystrophy (CALD) Market Expected to Reach $14.72 Billion by 2030 - Published: 2026-11-11 - Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md) - Topics: [News](https://healthcarenews.io/news.md) - Source: https://healthcarenews.io/news/global-cerebral-adrenoleukodystrophy-cald-market-expected-to-reach-14-72-billion-by-2030/ - Publication: Healthcare News - Publisher: Connectively (Terkel, Inc.) - Editorial policy: https://healthcarenews.io/editorial-policy/ [![The Business Research Company](https://www.einpresswire.com/image/medium/236757/tbrc.jpeg)](https://www.einpresswire.com/image/large/236757/tbrc.jpeg#1024x302) The Business Research Company [![Cerebral Adrenoleukodystrophy (CALD) Market Overview](https://www.einpresswire.com/image/medium/1241654/cerebral-adrenoleukodystrophy.jpeg)](https://www.einpresswire.com/image/large/1241654/cerebral-adrenoleukodystrophy.png#1024x768) Cerebral Adrenoleukodystrophy (CALD) Market Overview *The Business Research Company's Global Cerebral Adrenoleukodystrophy (CALD) Market Expected to Reach $14.72 Billion by 2030* **Expected to grow to $14.72 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%”** — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, November 11, 2026 /[EINPresswire.com](https://www.einpresswire.com/)/ -- "An in-depth look at the [cerebral adrenoleukodystrophy (CALD) market](https://www.thebusinessresearchcompany.com/purchaseoptions?id=21135&slug=cerebral-adrenoleukodystrophy-cald-global-market-report) reveals a sector experiencing significant growth and innovation. Driven by advances in genetic research and emerging treatment options, this market is set to expand rapidly in the coming years. Below, we explore the market size, key growth drivers, leading regions, and important trends shaping CALD’s future. Current and Projected Market Size of the Cerebral Adrenoleukodystrophy (CALD) Market The cerebral adrenoleukodystrophy (CALD) market has witnessed swift growth recently, with its value expected to rise from $7.54 billion in 2025 to $8.64 billion in 2026. This corresponds to a robust compound annual growth rate (CAGR) of 14.6%. The expansion during this historical period is largely due to advances in the genetic understanding of adrenoleukodystrophy (ALD), increased availability of stem cell transplantation treatments, the growth of rare disease registries, better awareness among neurologists, and the rise of specialty centers focused on rare disorders. Download a free sample of the [cerebral adrenoleukodystrophy (cald) market report](https://www.thebusinessresearchcompany.com/report/cerebral-adrenoleukodystrophy-cald-global-market-report): [https://thebusinessresearchcompany.com/sample\_request?id=37032138&type=smp&name=Cerebral%20Adrenoleukodystrophy%20%28CALD%29%20Market%20Report%202026&utm\_source=EINPresswire&utm\_medium=Paid&utm\_campaign=Nov\_PR](https://thebusinessresearchcompany.com/sample_request?id=37032138&type=smp&name=Cerebral%20Adrenoleukodystrophy%20%28CALD%29%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR) Looking ahead, the CALD market is poised for continued rapid growth, estimated to reach $14.72 billion by 2030 at a CAGR of 14.2%. This forecasted rise is fueled by greater adoption of gene therapy techniques, more investment in rare disease pharmaceutical development, expanded newborn screening programs, a stronger focus on personalized medicine, and enhanced collaboration between research institutions and clinical centers. Key trends during this period also include increased exploration of gene therapy approaches, wider implementation of early diagnostic screening, broader use of stem cell transplantation therapies, heightened rare disease awareness campaigns, and improved supportive care management. Understanding Cerebral Adrenoleukodystrophy (CALD) as a Disease Cerebral adrenoleukodystrophy (CALD) is a rare and progressive neurological condition primarily impacting males, caused by mutations in the ABCD1 gene. This disorder leads to the harmful buildup of very long-chain fatty acids in the brain, damaging the myelin sheath that protects nerve cells. CALD is a specific form of adrenoleukodystrophy (ALD) affecting the brain and spinal cord, resulting in symptoms such as cognitive decline, behavioral changes, and challenges with motor skills. View the full cerebral adrenoleukodystrophy (cald) market report: [https://thebusinessresearchcompany.com/report/cerebral-adrenoleukodystrophy-cald-global-market-report?utm\_source=EINPresswire&utm\_medium=Paid&utm\_campaign=Nov\_PR](https://thebusinessresearchcompany.com/report/cerebral-adrenoleukodystrophy-cald-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR) Key Factors Propelling the Growth of the Cerebral Adrenoleukodystrophy (CALD) Market One of the main forces driving the CALD market forward is the steady increase in healthcare spending worldwide. Factors such as aging populations, a rise in chronic illnesses, medical technological advancements, escalating drug prices, and broader health coverage contribute to this trend. Increased healthcare expenditure supports CALD market growth by facilitating the development of advanced diagnostic tools, funding cutting-edge treatments like gene therapy and stem cell transplants, and improving patient access to specialized care and early diagnosis. For example, in December 2024, the Centers for Medicare and Medicaid Services (CMS) reported that national health expenditures (NHE) in the United States grew by 7.5% in 2023, outpacing the 6.1% growth of the gross domestic product (GDP). Projections indicate that between 2023 and 2032, NHE will grow at an average annual rate of 5.6%, increasing healthcare’s share of GDP from 17.3% in 2022 to 19.7% by 2032. This upward trend in healthcare spending is a critical driver for the cerebral adrenoleukodystrophy market’s expansion. Regional Outlook Highlighting Fastest Growing Markets in CALD In 2025, North America held the largest share of the cerebral adrenoleukodystrophy market. The comprehensive market analysis includes regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Among these, Asia-Pacific and other emerging markets are expected to witness some of the fastest growth rates in the coming years due to increasing healthcare infrastructure development, improved diagnostic capabilities, and expanding awareness about rare diseases. What’s new in our 2026 market reports: • Market attractiveness scoring and analysis • Total addressable market (TAM) analysis • Company scoring matrix graphics and tables • Excel dashboards • Market hotspots infographics • Key technologies and future trends • Updated graphics and tables Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267 Email: marketing@tbrc.info The Business Research Company - [www.thebusinessresearchcompany.com](http://www.thebusinessresearchcompany.com) Follow Us On: • LinkedIn: [https://in.linkedin.com/company/the-business-research-company](https://in.linkedin.com/company/the-business-research-company)" Oliver Guirdham The Business Research Company [7882 955267]() [info@tbrc.info](mailto:info@tbrc.info) Visit us on social media: [LinkedIn](https://www.linkedin.com/company/the-business-research-company/) [Facebook](https://www.facebook.com/TheBusinessResearchCompany/) [X](https://twitter.com/tbrc_info) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. ![](https://www.einpresswire.com/tracking/article.gif?aid=954403147§ion=einpresswire&a=5GPS8k2VaYWsGNhC&r=Ohkp76qG8AiWTQ6s&i=i147G1WHuqiCmYKp) ## Related - [One-time base editing for sickle cell disease met its goal of a year free of severe crises, Beam says](https://healthcarenews.io/news/base-editing-for-sickle-cell-disease.md) - [A lab-grown blood vessel for dialysis patients whose fistulas fail is set for an FDA filing in November](https://healthcarenews.io/news/bioengineered-blood-vessel-for-dialysis-fda-filing.md) - [Half of myeloma patients given one CAR-T infusion after an early relapse were progression-free five years on](https://healthcarenews.io/news/car-t-first-relapse-myeloma-five-year-results.md) - [Stargardt disease has no approved treatment. A new trial tests a shot that limits vitamin A reaching the eye](https://healthcarenews.io/news/stargardt-disease-clinical-trial-city-rbp4.md)